Canadian Bio Med Systems, Inc., Today Announced a Revolutionary New Treatment for Glaucoma Being Developed in Conjunction With the University of Arizona
Posted on: Tuesday, 9 September 2008, 12:00 CDT
NEW YORK, MONTREAL, and SAN DIEGO, CA, Sept. 9 /PRNewswire-FirstCall/ -- Canadian Bio Med Systems Inc., a wholly owned subsidiary of ICBS Limited (OTCPK: ICBT), is pleased to announced a revolutionary new treatment for Glaucoma being developed in conjunction with the university of Arizona.
An exciting new drug is currently under development by Canadian Bio Med Systems, Inc. with their partner Ocular Therapeutics Inc, of San Diego, (CBMS) which may changed the paradigm of glaucoma therapy.
Glaucoma is a leading cause of blindness in the United States and the world. Glaucoma is a disease of the optic nerve, which carries images to the brain. Glaucoma is caused by the buildup of pressure within the eye although it is now thought that some forms of glaucoma can occur within eyes that exhibit "normal tension" or normal ranges of pressure.
A clear liquid, called the aqueous humor circulates within the front portion (anterior chamber) of the eye. A small amount of aqueous humor is produced constantly and an equal amount flows out of the eye through a microscopic drainage system. If this drainage system becomes blocked or constricted excess fluid can accumulate in the anterior chamber causing the intraocular pressure to rise and the possibility of glaucoma if this condition is not treated.
The current treatment for glaucoma consists of eye drops usually used one to two times per day. It also should be noted that in most instances, more than one drug is prescribed to control the intraocular pressure.
Because the eye drops used to control glaucoma are used so often, the largest problem is with patient compliance. Patients just don't use their drops as prescribed. In a recent study it was found that after six months of having the first prescription of glaucoma drugs, the patients only complied at a 40% level. That means only 40% of the eyes were getting the prescribed levels of glaucoma drugs. This problem is so endemic that there are articles monthly in ophthalmology journals on how best to improve patient compliance.
The market for glaucoma treatments is huge. A recent study completed at Johns Hopkins University indicates that worldwide in 2010 there will be 60.5ÃÂ million people with the most common form of glaucoma (open angle glaucoma) and that number increases to 79.6 million by 2020. This is an example of an age related disease that increases as the worldwide population ages, especially the so-called "baby boomers".
The product under development by ART at the University of Arizona has the remarkable prospect of needing to be used only once or twice per year by the patient. This will potentially change the paradigm of glaucoma treatment and vastly improve patient compliance.
"The development of this very important product in a very important and sizable markets." Said Richard H. Keates, MD, Chairman of Ocular Therapeutics, Inc. "The products being developed could make a considerable difference in the treatment of one of the most serious ophthalmic condition today."
Inter Canadian Business Service
CONTACT: Randy Bailey, (949) 228-4258; Source: ICBS Limited,http://www.icbs.ca/; Source: Canadian Bio Med Systems Inc.
Source: PRNewswire-FirstCall
Related Articles
- MDCT Angiography Helps Lead to Successful Treatment of Patients
- CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
- Health Canada Renews Funding to the Canadian Patient Safety Institute
- More Than Two-Thirds of Newly-Diagnosed Patients Who Are Prescribed Medications for OCD Receive Inadequate Therapy
- Alacrity Biosciences Announces Positive Results From a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
- Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
- New Treatment Guidelines Support Use of FUZEON(R) to Achieve Undetectable HIV in Treatment-Experienced Patients
- FDA Asks for More Data on Durham, N.C.-Based Drug Maker's Dry-Eye Treatment
- Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients
- LASIK Eye Treatment
 |
 |
User Comments (0)
RSS Feeds